Weibert R, Keane W, Shapiro F
Trans Am Soc Artif Intern Organs. 1976;22:439-43.
Carbenicillin appears to produce clinically important inactivation of aminoglycoside antibiotics in patients with severe renal failure. If combination carbenicillin/aminoglycoside therapy is used in patients with severe renal failure, the dose of carbenicillin must be adjusted to renal function and serum levels of both drugs should be monitored. Even with therapeutic serum carbenicillin levels (100-200 mug/ml), large doses of aminoglycosides may be required to achieve therapeutic serum levels and this may increase the risk of toxicity.
羧苄青霉素似乎会使严重肾衰竭患者体内的氨基糖苷类抗生素产生具有临床重要意义的失活。如果在严重肾衰竭患者中使用羧苄青霉素/氨基糖苷类联合疗法,羧苄青霉素的剂量必须根据肾功能进行调整,并且两种药物的血清水平都应进行监测。即使羧苄青霉素血清水平处于治疗范围(100 - 200微克/毫升),可能仍需要大剂量的氨基糖苷类药物才能达到治疗性血清水平,而这可能会增加毒性风险。